Strategic Funding SphingoTec recently closed a €5M Series C led by Think.Health Ventures with continued backing from Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK and Wellington Partners. This signals strong investor confidence and potential for collaboration on funded projects or joint development opportunities.

Market Expansion Recent product launches such as the AFIAS sphingotest penKid assay and the earlier penKid IB10 indicate active efforts to broaden diagnostic offerings for kidney function and acute conditions, presenting cross-sell opportunities to labs and hospitals seeking real-time biomarker solutions.

Clinical Focus Target indications include acute heart failure, acute kidney injury and circulatory shock, with expansion into obesity, cardiovascular risk and breast cancer. Engage clinical decision-makers and payers to explore diagnostics that support early management and prevention strategies.

Strategic Partnerships Cooperation with Boditech Med for AFIAS integration suggests openness to distribution and co-development models. Explore partnerships for regional commercialization, data sharing, and integrated biomarker platforms across Europe and Asia.

Scale and Resources With a global-facing platform and a lean team (11-50 employees) plus notable Series C funding, there is capacity to pilot multi-site studies, pursue contract research, and target larger healthcare systems while leveraging investor-backed growth to de-risk collaborative opportunities.